Physician profile
Hamza S Gorsi
NPI 1831487586
$81,065.48
in general payments reported to CMS, 2019-2025
12 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $126 · 2021: $4,590 · 2022: $251 · 2023: $19K · 2024: $23K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Travel and Lodging: $8,990 · Food and Beverage: $1,713 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,100.00 |
| Travel and Lodging | $8,989.96 |
| Food and Beverage | $1,713.03 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $75,753.14 | 2021-2025 | Koselugo |
| Astrazeneca Pharmaceuticals Lp | $4,465.00 | 2021 | |
| Sobi, INC | $175.47 | 2023 | |
| Servier Pharmaceuticals LLC | $165.08 | 2020-2025 | |
| Genentech USA, INC. | $128.75 | 2019 | |
| Genzyme Corporation | $125.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.51 | 2019 | |
| Emmaus Medical, INC. | $37.18 | 2023 | Endari |
| Jazz Pharmaceuticals INC. | $33.02 | 2025 | |
| Caris Mpi, INC. | $32.61 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $21.81 | 2022 | |
| Fennec Pharmaceuticals, INC. | $16.91 | 2023 | Pedmark |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Gorsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.